RESULTS
NSTEMI, nonobstructive coronary arteries, obstructive coronary artery disease
BLOOD, MYOCARDIAL INFARCTION
Biomarker results were available at baseline in 554 patients with MINOCA and 11 106 patients with MI‐CAD; at 1‐month follow‐up, biomarker results were available in 107 patients with MINOCA and 2755 patients with MI‐CAD (Figure Baseline Characteristics in Patients With MINOCA and MI‐CADData presented as numbers (with percentages) for categorical variables or medians (with interquartile ranges) for continuous variables. Information on clinical characteristics and in‐hospital revascularization was collected at the index hospitalization. Medications were considered at the time of blood sampling at baseline. BMI indicates body mass index; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; MI‐CAD, MI with obstructive coronary artery disease; MINOCA, MI with nonobstructive coronary arteries; NSTEMI, non–ST‐segment–elevation MI; PCI, percutaneous coronary intervention; RAAS, renin‐angiotensin‐aldosterone system; and STEMI, ST‐segment–elevation MI.On the basis of medical history or lipid treatment at admission.On the basis of cystatin C. Missing: n=17 patients with MINOCA and n=300 patients with MI‐CAD in the baseline cohort; n=28 patients with MI‐CAD in the follow‐up cohort.Overall, the time from onset of symptoms to blood sampling at baseline was 15.1 (8.1–21.3) hours in patients with MINOCA and 8.9 (3.9–17.3) hours in those with MI‐CAD. Blood samples were collected closer to the onset of symptoms in patients with STEMI compared with NSTEMI, in both the MINOCA and the MI‐CAD groups (Table Time From Symptom Onset to Blood Sampling at Baseline in the Total Cohort and Concentrations of Biomarkers Stratified by MINOCA or MI‐CAD and STEMI or NSTEMIData presented as medians (with interquartile ranges). GDF‐15 indicates growth differentiation factor 15; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐cTnT, high‐sensitivity cardiac troponin T; MI‐CAD, myocardial infarction with obstructive coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; NSTEMI, non–ST‐segment–elevation myocardial infarction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; and STEMI, ST‐segment–elevation myocardial infarction.